This study is in progress, not accepting new patients
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Gilead Sciences
- ID
- NCT04313881
- Phase
- Phase 3 Myelodysplastic Syndrome Research Study
- Study Type
- Interventional
- Participants
- Expecting 520 study participants
- Last Updated